株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

CountryFocus:日本の医療・規制・医療費償還制度の状況

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan

発行 GlobalData 商品コード 275366
出版日 ページ情報 英文 131 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.19円で換算しております。
Back to Top
CountryFocus:日本の医療・規制・医療費償還制度の状況 CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan
出版日: 2019年04月01日 ページ情報: 英文 131 Pages
概要

日本では今後、規制改革により医薬品の認証過程の迅速化・効率化が進むと見込まれています。そのため、世界各国の大手製薬企業が日本国内に研究開発 (R&D) センターを設立し、多額の資金を投じて市場開拓を進めようとしています。

当レポートでは、日本の医療関連市場の動向や、医療費償還制度および関連規制・制度について分析し、医薬品産業・医療装置産業の全体的構造・動向、医療費償還制度などの制度の概略・傾向、医療規制当局や各種規制の概要、日本経済・社会に関するマクロ的指標 (人口構造、医療インフラなど) といった情報を取りまとめてお届けします。

目次

  • エグゼクティブ・サマリー
  • 医薬品市場の概要
  • 医療機器市場の概要
  • 資本取引の分析
  • ポーターのファイブフォース分析
  • 市場アクセス
  • 日本国内の医療環境
  • 市場の機会と課題
図表

List of Tables

  • Table 1: Approved Biosimilars, Japan, 2018
  • Table 2: Top Five Therapeutic Areas by Drug Production Value ($B), Japan, 2017
  • Table 3: Ophthalmic Devices Market, Japan, Revenue ($M) and Market Share (%) of Major Companies, 2015
  • Table 4: Nephrology and Urology Devices Market, Japan, Revenue ($M) and Market Share (%) of Major Companies, 2016
  • Table 5: In Vitro Diagnostics Market, Japan, Revenue ($M) and Market Share (%) of Major Companies, 2017
  • Table 6: Diagnostic Imaging Market, Japan, Revenue ($B), 2015-2022
  • Table 7: Hospital Supplies Market, Japan, Revenue ($M) and Market Share (%) of Major Companies, 2017
  • Table 8: Medical Device Classification, Japan, 2016
  • Table 9: Patent Fees, Japan, 2019
  • Table 10: Trademark Fees, Japan, 2019
  • Table 11: Trade Fairs, Japan, 2019

List of Figures

  • Figure 1: Pharmaceutical Market, Japan, Revenue ($B), 2010-2017
  • Figure 2: Medical Device Market, Japan, Revenue ($B), 2015-2020
  • Figure 3: Country Profile, Japan, 2018
  • Figure 4: Pharmaceutical Market, Japan, Revenue ($B), 2010-2017
  • Figure 5: Pharmaceutical Market, Japan, Revenue Forecast ($B), 2018-2022
  • Figure 6: Pharmaceutical Exports ($B), Japan, 2010-2018
  • Figure 7: Top Export Partners, Japan, 2018
  • Figure 8: Pharmaceutical Imports ($B), Japan, 2010-2018
  • Figure 9: Top Import Partners, Japan, 2018
  • Figure 10: Pharmaceutical Supply Chain, Japan, 2019
  • Figure 11: Generic Drugs Market (% share), Japan, 2009-2017
  • Figure 12: Major Approved Biopharmaceuticals in Japan, Japan, 2016
  • Figure 13: Breakdown of Approved Biopharmaceuticals, Japan, 2016
  • Figure 14: Top 5 Therapeutic Areas by Annual Turnover ($B), Japan, 2017
  • Figure 15: Pharmaceutical Market, Major Players, 2017
  • Figure 16: Medical Device Market, Japan, Revenue ($B), 2015-2020
  • Figure 17: Medical Device Market, Japan, Revenue Forecast ($B), 2021-2025
  • Figure 18: Medical Device Market, Japan, Revenue by Segment ($B), 2018
  • Figure 19: Ophthalmic Devices Market, Japan, Revenue ($B), 2015-2022
  • Figure 20: Ophthalmic Devices Market, Japan, Market Share of Major Players (%), 2015
  • Figure 21: Nephrology and Urology Devices Market, Japan, Revenue ($B), 2015-2022
  • Figure 22: Nephrology and Urology Devices Market, Japan, Market Share of Major Companies (%), 2016
  • Figure 23: In Vitro Diagnostics Market, Japan, Revenue ($B), 2015-2022
  • Figure 24: In Vitro Diagnostics Market, Japan, Market Share of Major Players (%), 2017
  • Figure 25: Diagnostic Imaging Market, Japan, Revenue ($B), 2015-2022
  • Figure 26: Diagnostic Imaging Market, Japan, Market Share of Major Players (%), 2016
  • Figure 27: Hospital Supplies Market, Japan, Revenue ($B), 2015-2022
  • Figure 28: Hospital Supplies Market, Japan, Market Share of Major Players (%), 2017
  • Figure 29: Diagnostic Market, Japan, Revenue ($B), 2015-2020
  • Figure 30: Diagnostic Market, Japan, Revenue ($B), 2021-2025
  • Figure 31: Medical Device Market, Japan, Revenue ($B) of Major Companies, 2017
  • Figure 32: Deal Value and Deal Count, Pharmaceutical Market, Japan, 2018-2019
  • Figure 33: Deal Value and Deal Count Quarterly, Pharmaceutical Market, Japan, 2018-2019
  • Figure 34: Deal Value and Deal Count Sub-Types, Pharmaceutical Market, Japan, 2018-2019
  • Figure 35: Top Five Therapy Areas by Deal Value, Pharmaceutical Market, Japan, 2018-2019
  • Figure 36: Top Five Therapy Areas by Deal Number, Pharmaceutical Market, Japan, 2018-2019
  • Figure 37: M&A Deals by Therapy Area, Pharmaceutical Market, Japan, 2018-2019 (by value and by number)
  • Figure 38: Venture Financing Deals by Therapy Area, Pharmaceutical Market Japan, 2018-2019(by value and by number)
  • Figure 39: Medical Device Market Deals (by deal value, $M), Japan, 2018
  • Figure 40: Medical Device Market Deals (by deal count), Japan, 2018
  • Figure 41: Medical Device Market Deals Share (by deal count), Japan, 2018
  • Figure 42: Medical Device Market Deals Share (by deal value), Japan, 2017-2018
  • Figure 43: Medical Device Market Deals, Japan, Top Therapy Area by Deal Value, 2018
  • Figure 44: Medical Device Market Deals, Japan, Top Therapy Area by Deal Number, 2018
  • Figure 45: Medical Device Market Deals, Japan, M&A Deals by Therapy Area, 2018
  • Figure 46: Medical Device Market Deals, Japan, Venture Financing Deals by Therapy Area, 2018
  • Figure 47: Medical Device Market Deals, Japan, Private Equity Deals by Therapy Area, 2018
  • Figure 48: Organization of the Health System, Japan, 2018
  • Figure 49: Reimbursement Pricing for New Drugs, Japan, 2018
  • Figure 50: Public Insurance Schemes, Japan, 2016
  • Figure 51: Public Insurance Schemes, People Insured by Scheme (%), Japan, 2016
  • Figure 52: Financial flow based on insurance flows, Japan, 2016
  • Figure 53: Cross-subsidy mechanism, Japan, 2017
  • Figure 54: Out-of-Pocket Expenditure (% of total expenditure on health), Japan, 2010-2017
  • Figure 55: Annual Rate of Change (%), Medicines and health fortification Price Index, Japan, 2010-2018
  • Figure 56: Types of Premiums, Japan, 2016
  • Figure 57: Pricing Policies, Japan, 2017
  • Figure 58: Ministry of Health, Labour and Welfare, Organization Chart, 2018
  • Figure 59: Organization of PSEHB and PMDA, Japan, 2018
  • Figure 60: Drug Approval Process, Japan, 2018
  • Figure 61: Drug Approval Process Timeline, Japan, 2018
  • Figure 62: Patent Approval Process, Japan, 2016
  • Figure 63: Trademark Process Timeline, Japan, 2017
  • Figure 64: Clinical Trial Notification Process, Japan, 2018
  • Figure 65: Layout of Package Insert Based on Revised Guidelines for Preparation, Japan, 2018
  • Figure 66: Health Care 2035, Japan, 2019
  • Figure 67: Health Care 2035, Japan, 2019
  • Figure 68: Hospitals (number), Japan, 2010-2017
目次
Product Code: GDHC0077CHR

GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan",. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Japan. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Japan. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.

In 2010, the Japanese pharmaceutical market was worth $67.5B, which decreased to an estimated $61.8B in 2017 at a negative Compound Annual Growth Rate (CAGR) of 2%. The Japanese medical devices market was valued at $48.3B in 2015, which increased to $52.2B in 2017. The market is expected to grow at a CAGR of 4.1% from $54.5B in 2018 to $59.4B in 2020. Regulatory reforms have led to faster and more efficient drug approval processes. This has led to international pharmaceutical companies establishing R&D centers and increasing their investments in Japan.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the Japan, and includes -

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Daiichi Sankyo, Astellas, Roche, Takeda, and Otsuka) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Abbott, Roche, Terumo and Fujitsu)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of Japan
  • Porter's five forces analysis for pharmaceutical and medical devices market of Japan
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunitiesand challenges to growth in the Japanese healthcare market.

Reasons to buy

The report provides information on the healthcare, regulatory, and reimbursement landscape in the Japan, and includes -

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Daiichi Sankyo, Astellas, Roche, Takeda, and Otsuka) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Abbott, Roche, Terumo and Fujitsu)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of Japan
  • Porter's five forces analysis for pharmaceutical and medical devices market of Japan
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Japanese healthcare market.

Table of Contents

  • Executive Summary
  • Overview of Pharmaceutical Market
  • Overview of Medical Device Market
  • Deals Analysis
  • Porter's Five Forces Model
  • Market Access
  • Country Healthcare Landscape
  • Opportunities and Challenges

Appendix

Back to Top